Paper of the month: Endocrine Therapy in HEGR2 neg mBC
31.08.2018
A review that summarized the available data on endocrine therapy for premenopausal women with HER2-negative hormone receptor-positive metastatic breast cancer (MBC) has been published in the Oncologist.
During the past 30 years, the incidence of metastatic breast cancer (MBC) in women aged 25-39 years has slightly increased. Up to date, no comprehensive review exists for therapeutic approaches in that patient population. Therefore, this review aimed to provide clinicians with an overview on the available data regarding endocrine treatment of hormone receptor-positive MBC in premenopausal women and to indicate potential future directions of research.
Tancredi R, Furlanetto J, Loibl S. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. Oncologist. 2018; 23:974-981.
News
-
28.09.2023 Translational Work from GeparSepto published
The prognostic and predictive potential of CAV1/2 expression was analysed in the GeparSepto trial (GBG 069).
Mehr ... -
27.09.2023 GBG research at SABCS
GBG will present several posters at the San Antonio Breast Cancer Symposium 2023
Mehr ... -
21.09.2023 New review on Immune Cell Infiltration published
A review from the International Immuno-Oncology Biomarker Working about tumor immunology was published in the journal of pathology.
Mehr ... -
07.09.2023 Save the date! GBG Annual Scientific Meeting 2024
Das 21. Annual Scientific Meeting 2024 wird am 29.2. bis 1.3. in Frankfurt stattfinden.
Mehr ...